April 21, 2011 -- ClinTec International is delighted to announce that it has been named as a recipient of the Queen’s Award for Enterprise. This accolade, bestowed by Her Majesty The Queen on the advice of the Prime Minister and advisory committees, was announced on the 21st of April 2011, Her Majesty’s birthday, and is widely recognised as the most prestigious business accolade for any organisation operating in the UK. A rigorous judging process ensures that the Queen’s Awards are indicative of the highest standards of quality and excellence.
ClinTec, a full service contract clinical research organisation, was granted the award under the category of International Trade in recognition of its substantial growth in overseas revenue and commercial success in the last 3 years, achieving an increase in overseas sales in excess of 250% from 2007–2009. ClinTec has established operations in over 40 countries across 5 continents and is recognised as a specialist in delivering excellence in clinical research within both established and emerging markets. ClinTec was one of the first global contract clinical research organisations to establish a presence in the Middle East and North Africa and has continued to expand into South Africa, India, Latin America and South East Asia. Concurrently, ClinTec has continued to strengthen its position in the more traditional European and North American markets.
Speaking about the Queen’s Award, ClinTec President, Founder and CEO, Dr Rabinder Buttar, stated: “I am delighted and honoured that the success of ClinTec has been recognised with such a prestigious accolade as the Queen’s Award for Enterprise. I’m proud of the entire ClinTec team and our motto ‘fast, flexible, focused’ has empowered us to deliver outstanding service to our clients. We have always recognised the importance of our international opportunities and have been at the forefront of entering the emerging markets of clinical research. The Queen’s Award for Enterprise in International Trade is a fantastic recognition of the efforts we’ve made. I’d also like to take this opportunity to thank our clients, many of whom have been working with us for over a decade. Due to the high degree of trust they have in our business and our ability to deliver, they have enabled us to partner with them and grow our business in exact alignment with their evolving needs”.
About ClinTec International
ClinTec International is a global contract clinical research organisation, established in 1997 by Dr Rabinder Buttar, the company’s President and CEO. ClinTec International has a presence in over 40 developed and emerging countries, covering Western Europe, the US, Central & Eastern Europe, the Middle East and North Africa, Sub-Saharan and South Africa, Latin America, India and the Asia/Pacific region.
In addition to ClinTec International’s vast expertise in oncology, the organisation has also conducted over 400 clinical trials in other therapeutic areas including anti-infectives, cardiology, dermatology, gastroenterology, neurology, respiratory medicine and rheumatology. ClinTec International excels in conducting clinical studies in diverse geographical locations, supported by a team of world-class project managers and clinical research associates. ClinTec International’s ‘fast, flexible and focused’ approach to clinical research ensures an added advantage to the drug development process. The organisation’s range of services includes Clinical Monitoring and Project Management, Regulatory Affairs, Medical Writing, Data Management and Biostatistics, Global Clinical Resourcing, Quality Assurance, Drug Development Consultancy and Clinical Training courses.
For further information please contact:
Bobby Bal, Senior Director Corporate Development, ClinTec International Headquarters: +44 (0) 141 226 1120 or email@example.com
For more information about ClinTec, please visit www.clintec.com